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Abstract
The 2009 influenza pandemic provided an opportunity to observe dynamic changes of the hemagglutinin (HA) and
neuraminidase (NA) of pH1N1 strains that spread in two metropolitan areas -Taipei and Kaohsiung. We observed cumulative
increases of amino acid substitutions of both HA and NA that were higher in the post–peak than in the pre-peak period of
the epidemic. About 14.94% and 3.44% of 174 isolates had one and two amino acids changes, respective, in the four
antigenic sites. One unique adaptive mutation of HA2 (E374K) was first detected three weeks before the epidemic peak. This
mutation evolved through the epidemic, and finally emerged as the major circulated strain, with significantly higher
frequency in the post-peak period than in the pre-peak (64.65% vs 9.28%, p,0.0001). E374K persisted until ten months
post-nationwide vaccination without further antigenic changes (e.g. prior to the highest selective pressure). In public health
measures, the epidemic peaked at seven weeks after oseltamivir treatment was initiated. The emerging E374K mutants
spread before the first peak of school class suspension, extended their survival in high-density population areas before
vaccination, dominated in the second wave of class suspension, and were fixed as herd immunity developed. The tempo-
spatial spreading of E374K mutants was more concentrated during the post–peak (p=0.000004) in seven districts with
higher spatial clusters (p,0.001). This is the first study examining viral changes during the naı ¨ve phase of a pandemic of
influenza through integrated virological/serological/clinical surveillance, tempo-spatial analysis, and intervention policies.
The vaccination increased the percentage of E374K mutants (22.86% vs 72.34%, p,0.001) and significantly elevated the
frequency of mutations in Sa antigenic site (2.36% vs 23.40%, p,0.001). Future pre-vaccination public health efforts should
monitor amino acids of HA and NA of pandemic influenza viruses isolated at exponential and peak phases in areas with high
cluster cases.
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Introduction
Newly emerged triple reassortant 2009 pandemic influenza A
(HIN1) (pH1N1) viruses were detected in patients with respira-
tory illness in Mexico and the United States in early April, 2009
[1–3]. These novel viruses rapidly spread worldwide through
human-to-human transmission. The World Health Organization
(WHO) announced its pandemic alert levels as phase 4–5 in late
April, 2009, elevated to phase 6 on June 11, 2009, and then
moved to the post-pandemic period on August 10, 2010. As of
August 1, 2010, more than 214 countries and overseas territories
had reported laboratory-confirmed cases of pH1N1, including
over 18449 deaths (http://www.who.int/csr/don/2010_08_06/
en/index.html). How these novel influenza viruses underwent
spontaneous evolution [4,5] and dynamic changes over different
time periods and various places within different epidemiological
entities and intervention strategies is an important public health
issue.
Hemagglutinin (HA) and neuraminidase (NA) are the two most
important envelope proteins of influenza viruses, frequently
encountering external antibody selection pressure. HA, a major
surface glycoprotein of influenza virus responsible for its
attachment to host cells and initiating viral entry, plays a
significant role in inter-species transmission, emergence of novel
influenza viruses, viral pathogenesis and immunity [6,7]. The NA
is involved not only in progeny virion release and spread of the
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have a role in HA-mediated membrane fusion and assisting
efficient replication of influenza viruses [8–10]. In addition, the
increased levels of accumulated antibodies against HA and NA at
the population level also facilitate influenza virus to undergo
antigenic drifts under the selective pressure of herd immunity [11–
13]. After the introduction of pH1N1 viruses into the human
population, their variations in the amino acids of HA and NA
proteins have been reported [14–19]; however these studies lacked
important epidemiological attributes, including temporal and
geographical comparisons and with or without public health
prevention efforts such as school suspension and vaccination.
Therefore, the impact of amino acids changes of HA and NA of
these pH1N1 viruses related to epidemiological characteristics,
clinical severity, and after public health interventions has remained
unclear.
Taiwan, with a population density of 639/km
2,i sl o c a t e da t
the junction between subtropical and tropical regions of South-
East Asia. The two metropolitan cities, Taipei and Kaohsiung
situated in northern and southern Taiwan, respectively, have
much higher population densities (9593/km
2 and 9948/km
2)
[20]. The first imported case of pH1N1 in Taiwan was
identified on May 20, 2009 and the first indigenous pH1N1
case was confirmed five days later [21]. The community
outbreak occurred in early J u l y ,2 0 0 9 .T h e n ,t h ep H 1 N 1
quickly swept through the whole Taiwan and the first fatal case
was reported on July 30, 2009 [21]. As of July 31, 2010, a total
of 46 fatal cases infected with the pH1N1 were laboratory-
confirmed in Taiwan (http://flu.cdc.gov.tw/public/Data/
0841041371.pdf). For controlling the spread of pH1N1 in
Taiwan, a 2-3-5 class suspension intervention was implemented
on September 1 (weeks 35), 2009 for all students who were 18
years old or younger with suspected influenza like illness (ILI) or
a positive rapid influenza A antigen test [22]. Under the 2-3-5
policy, any school class must be suspended if more than 2
students were ILI cases (fitting the above criteria) within a time
interval of 3 days. Students from suspended class were required
to stay home for at least 5 days before their return to school. A
pH1N1-specific mass vaccination program targeted at elemen-
tary through junior high school students free of charge began on
November 16, 2009 [23]. A nationwide vaccination program
was later launched on December 12, 2009. As of July 25, 2010,
the overall vaccine coverage rates were 24.6% in the general
population and 76.9% among targeted schoolchildren. After the
circulation of this novel pH1N1 through a series of transmission
chains among human populations in the two metropolitan cities
with high population densities, Taipei and Kaohsiung, we were
interested to determine whether dynamic changes of amino
acids residues of HA and NA occurred at different epidemic
periods in 2009–2010.
The specific aims of this study were: (1) to examine the
variations in nucleotide and amino acid sequences and co-
mutations of HA and NA of the pH1N1 viruses isolated in the
post-peak period versus in the pre-peak period of the epidemic in
Taipei and Kaohsiung from June 2009 through October 2010, (2)
to compare viral mutation rates and qualitative amino acid
changes at receptor-binding sites (RBS), antigenic sites and N-
glycosylation sites before and after the implementation of three
public health interventions, including anti-viral program, school
class suspension and vaccination, and (3) to analyze the
epidemiologically tempo-spatial conditions in Taipei City that
are associated with the spread of the unique mutant of HA of
pH1N1 (gradually becoming the dominant strains after the peak of
epidemic).
Materials and Methods
Study Design and Study Populations
Since influenza is transmitted human-to-human, we initiated
virological surveillance by selecting one hospital from each
metropolitan located in northern and southern Taiwan, respective-
ly. A cross-sectional study design targeting laboratory-confirmed
influenza patients with mild or severe clinical manifestations was
implemented. Patients with influenza like illness (ILI) or ILI with
severe complications involving any one of the following clinical
manifestations within four weeks requiring hospitalizations were
recruited for the study: pulmonary complications, neurological
complications, myocarditis or pericariditis, invasive bacterial
infection or intensive care unit admission (http://www.cdc.gov.
tw/ct.asp?xItem=7500&ctNode=920&mp=5) from the National
Taiwan University Hospital (NTUH) in Taipei (northern Taiwan,
subtropical climate) and Yuan’s General Hospital (YGH) in
Kaohsiung (southern Taiwan, tropical climate) from June 1, 2009
through October 31, 2010. Their nasopharyngeal or throat swabs
were collected for isolation of the pH1N1 viruses and subsequent
virological investigation. This research project was approved by the
ResearchEthicsCommittee,InstitutionalReviewBoardofNational
Taiwan University Hospital (IRB #200911013R) and the Ethics
Committee of Yuan’s General Hospital (IRB #2009110501B).
Subjects enrolled in this study provided written informed consent
for collecting clinical samples for virological testing. All the data
analyses of isolated influenza virus strains, clinical and epidemio-
logical information were processed and operated anonymously.
Laboratory Tests
1. Isolation of pH1N1 viruses. To obtain more isolates of
pH1N1, we used Madin-Darby Canine Kidney cells (MDCK)
(CCL34: American Type Culture Collection, Rockville, MD,
USA) to culture the virus and subsequently confirmed the results
with reverse transcription-polymerase chain reaction (RT-PCR) at
NTUH in Taipei. In Kaohsiung, specimens were first screened
with rapid influenza virus antigen screening (Genzyme
Diagnostics, USA) and the positive samples were then confirmed
with RT-PCR during the study period to save manpower expenses
at a regional hospital (YGH). All the positive pH1N1 viruses had
one passage in MDCK cells and were stored at 280uC for further
use.
2. Hemagglutination inhibition (HI) test. Human serum
samples were tested for their antibody responses against the
pH1N1 viruses by HI assay. The HI procedure was performed
according to the protocol used by the Centers for Disease Control
and Prevention in the United States (US-CDC). Briefly, the
human tested serum specimens were pre-treated with receptor
destroying enzyme (Denka Seiken Co., Ltd, cat # 370013) to
remove non-specific inhibitors. HI assays were performed in V-
bottom 96-well microtiter plates with 0.5% turkey’s erythrocytes.
HI serotiter was defined as the highest dilution of the tested serum
sample showing complete inhibition of hemagglutination of 4 units
of HA of the pH1N1.
3. Micro-Neutralization (MNt) assay. The MNt assay used
the laboratory protocol from the US-CDC with slight
modification. Briefly, human serum samples were heat
inactivated at 56uC for 30 minutes, and were prepared using
two-fold serial dilutions in a 50-mL volume of virus diluent (Eagles’
MEM) in 96-well microtiter plates with flat bottom. The diluted
sera were then mixed with an equal volume of virus diluent
containing the tested pH1N1 influenza virus strain at 2610
2 tissue
culture infectious doses with 50% cytopathic effect (TCID)50/mL.
Four control wells of virus plus virus diluent (VC) and virus diluent
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incubation at 37uC in a 5% CO2 humidified atmosphere for one
hour, 100 mL of MDCK cells at 1.5610
4/mL were added to each
well. The plates were incubated at 37uC, 5% CO2 for 18–20 hrs.
The monolayers were then washed with phosphate buffered saline
(0.01 M PBS, pH 7.2) and fixed in cold 80% acetone in PBS for
10 minutes. The presence of viral proteins was detected by
enzyme-linked immunosorbent assay at room temperature with a
monoclonal antibody against the NP of influenza A (MAB 8257
and 8258, Millipore, MA, USA). The horseradish peroxidase-
labeled goat anti-mouse immunoglobulin G (IgG) (Cat #074-
1802, Kirkegaard & Perry, Gaithersburg, MD, USA) was used as a
secondary antibody. After color formation in the final step, the
absorbance was measured at 490 nm (A490) The average A490
was determined for quadruplicate wells of virus-infected (VC) and
mock-infected (CC) control wells, and a neutralizing endpoint was
determined by using a 50% inhibition of the infected virus specific
signal. The endpoint titer50 was expressed as the reciprocal of the
highest dilution of serum with A490 value less than X, where
X=[(mean A490 of VC wells)2(mean A490 of CC wells)]/2 +
(mean A490 of CC wells).
4. Nucleotide sequencing of HA and NA genes of pH1N1
viruses. Viral RNA was extracted with the Qiagen RNA mini
kit (Qiagen, Germany). The HA domain of the HA gene was
amplified by one step RT-PCR (SuperScript
TM One-Step RT-
PCR with Platinum Taq, Invitrogen, Life Technologies, CA,
USA). Primer, Uni-12 (59-AGC AAA AGC AGG-39) was used for
cDNA synthesis [24]. Two primer pairs were used for HA gene
amplification: (1) HA-uniF (59-AGC AAA AGC AGG GGA AAA-
39), HA-R1 (935-59-ATA TTC TGA AAT GGG AGG CTG
GTG-39), and (2) HA-F2 (605-59-GTG CTG ACC AAC AAA
GTC TC-39) HA-uniR (59-AGT AGA AAC AAG GGT GTT
TT-39). Another two primer pairs were used for HA genome
sequencing: (1) HA-SF1 (41-59-CCG CAA ATG CAG ACA CAT
TA-39), HA-SR1 (759-59-CGG CTC TAC TAG TGT CCA G-
39) and (2) HA-SF2 (678-59-GTT CAA GCC GGA AAT AGC-
39), HA-SR2 (1674-59-CCC ATT AGA GCA CAT CCA GAA-
39). In order to analyze the residue change of 374 located at stalk
region of HA2, partial genome (nucleotides, 996–1298) was
sequenced by using primers: 996F (996-59- CAC AGG ATT GAG
GAA T-39), 1298R (1298- 59-CAG GAA ACC ATC ATC AAC-
39) and 1053F (1053-59-CGG TTT CAT TGA AGG GGG-39).
The first reverse transcription from RNA to cDNA was
performed at 50uC by incubation for 50 minutes; the PCR
reaction started by denaturing at 94uC for 6 minutes, and
amplified in 40 cycles (ABI 2700, Applied Biosystems, CA, USA)
under the following conditions, 94uC for 30 seconds(s); 53uC for
30 s, 72uC for 80 s and a final extension at 72uC for 10 minutes.
The PCR products were analyzed by electrophoresis in a 2%
agarose gel and visualized by staining the gels with ethidium
bromide. They were further purified and sequenced using an ABI
Model 3730XL DNA analyzer with ABI Terminator Cycle
Sequencing Ready Reaction Kit, V3.1 (Applied Biosystems, CA,
USA). Nucleotide sequence analysis and alignment were per-
formed using the Mega 4.1. For NA nucleotides sequence analysis,
the nucleic acid extraction, RT-PCR and sequencing were
performed according to the methods used for HA sequences
analysis except 51uC used for annealing and different primer sets
for amplification and sequencing. Two primer pairs were used for
NA gene amplification: (1) NA-uniF (59-AGC AAA AGC AGG
AGT-39); NA-R1 (893-59-CCA TGC CAG TTA TCC CTG-39)
and (2) NA-F2 (523-59-GAG TCA GTC GCT TGG TCA-39);
NA-uniR(59-AGT AGA AAC AAG GAG TTT TTT-39). Another
two primer pairs were used for NA fragment (1401nucleotides)
sequencing: (1) NA-SF2 (721-59-AAT GAC CGA TGG ACC
AAG-39), NA-SR2 (1332-59-GGA TAT GCT GCT CCC GCT
AG-39) and (2) NA-SF1 (41-59-GTA TGA CAA TTG GAA TGG
C-39); NA-SR1 (659-59-CTC CAA CTC TTG ATA GTG TCT
G-39).
5. Quantitative real-time RT-PCR. Viral RNA was
extracted from 200 mL of virus by Lab Turbo Virus Mini kit
(Taigen Bioscience Coporation, Taipei, Taiwan) and subjected to one
step RT-PCR using Precision one step qRT-PCR MasterMix (Primer
Design, Southampton, United Kingdom) and ABI PRISM 7500 Fast
Real-Time PCR system (Applied Biosystems, USA). The condition for
PCR was started at 95uC for denaturing 8 minutes, then at 95uC, 10 s
and 60uC, 31 s for 45 cycles using primers (FluA-F :59- AAGA-
CCAATCCTGTCACCTCTGA-39;F l u A - R:5 9-CAAAGCGTC-
TACGCTGCAGTCC-39) and TaqMan probe (FluA probe: 59FAM
–TTTGTGTTCACGCTCACCG T–39BBQ). The viral loads in the
original samples were measured by using influenza M-gene RNA
derived from M-gene carried in plasmid (pGEM-T Easy Vector, #
A1360, Promega, USA) as the standard.
Data Analysis and Statistics Tests
1. Epidemiological data analyses on risk factors. Univariate
analyses on factors, including age, gender, population density,
residential district, time intervals (weeks) of before, during and after
the starting of different vaccination programs targeting at various
populations and disease severity that might affect the differences in
frequency of amino acid changes between pre-peak and post–peak
periods of the epidemic were assessed by Chi-square tests. The
important variables including the pre- and post-peak periods of the
2009 epidemic, the phases before and after initiation of vaccination
program, gender, age, residential districts with spatial clustering, levels
of population density were used to run stepwise multivariate logistic
regression analysis.
2. Tempo-spatial analyses and statistic tests. To further
analyze the temporal and spatial spread of pH1N1 virus mutants
with E374K, we classified eight time stages as maps [(1) Weeks
21–33 (pre-peak and pre-class suspension), (2) weeks 34–35 (the
first detection of E374K mutant at week 34, the first week
implemented class suspension policy at week 35), (3) week 36, (4)
week 37 (peak of epidemic), (5) week 38, (6) week 39, (7) week 40,
and (8) weeks 41–52 (week 44+: post-vaccination)], based on the
pre-, during and post-epidemic peak periods of epidemic curve in
Taipei City and nearby Taipei County. The geographical unit
was determined, according to the administrative districts with
known population density (person/km
2) in 2009. The GIS
software of ArcGIS (ArcMap, version9.2; ESRI Inc., Redlands,
CA, USA) was applied to presenting the emergence and further
spatial spread of E374 K mutants in each time period over eight
time stages.
In order to examine the spatial clustering of E374K mutants in
Taipei City and County, we applied Moran’s I to test the presence
of global spatial clustering for the different time stages. The local
indicators of spatial association (LISA) were used for further
identifying local spatial clusters in post-peak epidemic periods
stratifying by before versus after the implementation of 1
st day of
vaccination (21
st –43
th week vs 44
th–52
nd week) on November 1
st,
2009, once global autocorrelation spatial showed statistically
significant. Global Moran’s I was used to evaluate whether the
tested districts with clustering tendency, which range from 21t o
+1. A reading close to 1 indicates strong spatial autocorrelation
and vice versa, with zero indicating randomness. LISA was used to
identify where clusters were located. A negative value of LISA
reflects dissimilarity with neighbors, while a positive value means
similarity, and zero refers to randomness [25].
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Comparison of the positive detection rates of pH1N1 in
northern and southern Taiwan
In order to monitor molecular changes of pH1N1 virus in the
two metropolitan areas, clinical specimens from ILI patients with
and without severe complications from June 1, 2009 to October
31, 2010 were collected. The pH1N1 viruses were identified
initially by culture or rapid screening tests and finally confirmed
by RT-PCR method. The weekly distributions of pH1N1 positive
detection rates in Taipei and Kaohsiung during this study period
were quite similar (Figure 1). Our analyses on isolation rates of
pH1N1 in Taipei and in Kaohsiung were 16.47% (1024/6218)
and 16.23% (682/4201) respectively, from week 22, 2009 to week
30, 2010. However, detailed analyses on the isolation rates of
pH1N1 in Taipei and in Kaohsiung during the same time period
(from week 22, 2009 to week 52, 2009) with the specimens
collected for improved comparison were 19.07% (1024/5371)
and 16.68% (634/3801), respectively. In other words, the
isolation rate in Taipei was higher than that in Kaohsiung
though the patterns were similar in both of these metropolitan
areas. The first peak in positive rates occurred at the 37th week
(September 13–19, 2009) in Taipei and at the 39th week
(September 27–October 3, 2009) in Kaohsiung. Furthermore,
both the exponential increasing and decreasing phases of the
positive pH1N1 rates in Kaohsiung were two weeks later than
those in Taipei. Finally, pH1N1 positive rates in these two cities
decreased sharply at the end of 2009 and few positive cases were
detected sporadically in 2010.
Analysis of the diversity of amino acid residues and
dynamic changes of antigenic sites and receptor-binding
sites in HA1 of pH1N1 before and after vaccination
The complete HA1 and partial HA2 nucleotide regions (HA1:
52–1029 nucleotides; HA2: 1033–1637 nucleotides) of pH1N1
strains were amplified and sequenced. Using vaccine strains, A/
California/07/2009(H1N1) as a reference strain for alignment, 78
available sequenced strains (collected from June 11, 2009 to
August 2, 2010, including 50 strains from Taipei and 28 strains
from Kaohsiung), showed high conservation, with 99.48% and
99.07% identities in the nucleotides and the amino acid sequences
of HA, respectively. The average substitution rates of nucleotides
and amino acids for HA were 5.04610
23 per nucleotide per gene
and 9.60610
23 per amino acid per protein, respectively. The
number of amino acid differences in HA between the Taiwanese
isolates and the vaccine strain [A/California/07/2009(H1N1)]
ranged from 3 to 7. There was a trend of increasing frequency of
cumulative numbers of amino acid substitutions over the weekly
time periods (Figure 2). The frequency of pH1N1 with cumulative
numbers of amino acids (equal to and greater than 5) was
significantly higher in the post–peak period of the epidemic than
those pH1N1 isolated at the pre-peak period (74.6%, 47/63 vs
6.67%, 1/15) (p,0.0001, Table 1).
The amino acid residues corresponding to the predicted four
antigenic sites Ca, Cb, Sa and Sb located at the globular region
(HA1) [26] of the 174 Taiwanese pH1N1 strains [available partial
HA nucleotides 261–1029, amino acid 70–343, numbering
without signal peptide (17 amino acids)] were compared to the
US early isolate (A/California/7/2009). Before August 25, 2009
Figure 1. Weekly distributions of positive rates of pH1N1 isolated from NTUH and YGH in Taiwan, 2009–2010. NTUH: National Taiwan
University Hospital located in Taipei; YGH: Yuan’s General Hospital (YGH) located in Kaohsiung. The time frames of different public health prevention/
control measures was indicated with arrows.
doi:10.1371/journal.pone.0031162.g001
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with S203S (13.16%, 5/38) isolated. The S203T, located at
antigenic site Ca, was first detected on May 24, 2009 (week 21)
and their frequencies were extremely high at 100% (2/2), 78.57%
(11/14) and 94.44% (34/36) in June, July and August, 2009,
respectively and reached 100% since August 30, 2009 (week 35).
These results indicated that 97.13% (169/174) of pH1N1 isolates
had amino acid residue substitution of S203T [counting the
number from the initial codon without signal peptide] (Figure 3).
Besides the S203T, the frequencies of pH1N1 with other
substitutions as one and two more amino acids changes at all four
antigenic sites were much lower as 14.94% (26/174) and 3.44%
(6/174), respectively (Figure 3). However, their overall frequency
of amino acid substitutions at all four antigenic sites of HA1, with
the exception of S203T, was higher in viruses isolated at post-peak
period (19.59%, 19/97) than those at pre-peak period (16.88%,
13/77, p=0.648), although the differences were not statistically
significant. The ranking of frequencies of amino acid mutations
from the highest to the lowest observed was 19, 14, 3 and 2 at the
antigenic sites of Ca, Sa, Sb and Cb, respectively [Figure 3, 4A].
To more clearly describe the dynamic antigenic changes of this
pH1N1 related to the timing of vaccination, we divided the post-
epidemic time period into three phases: (1) pre-vaccination phase
(Weeks 37–43, September 13–October 31, 2009), (2) during the
on-going vaccination campaign phase [Weeks 44–50, November
1–December 19 (December 12+7 days for antibody production for
evaluating different levels of herd immunity, 2009)], and (3) post-
nation-wide vaccination campaign phase (.Week 50, after
December 19, 2009). The overall frequencies of pH1N1 viruses
with amino acid substitutions in all four antigenic sites in each of
the three phases were 13.16% (5/38), 11.76% (2/17) and 28.57%
(12/42), respectively [p=0.149]. All the residue changes at the
four antigenic sites from the pre-peak period of the 2009 epidemic
through the pre-vaccination phase of the post-peak period of the
2009 epidemic (Figure 3) were examined, including: (1) site Ca
[with the most variations involving R205K (6 strains), D222G/E(4
strains), A141S(1 strain), I166F (1 strain)]; (2) site Cb [L70P(2
strains)]; (3) site Sa [P124S (1 strain), K154N(1 strain), K163R(1
strain)]; and (4) site Sb [L191I (1 strain), Q193H (1 strain)] (shown
as green zone in Figure 3). Interestingly, all these variants no
longer were detected during the post-vaccination phase. However,
there were also pH1N1 variants with amino acid substitutions at
five locations in the three antigenic sites identified only at post-
nation-wide vaccination campaign phase (after December 19,
2009, shown as yellow zone in Figure 3), including site Ca [K142R
(1 strain)], site Sa [N125D (9 strains), N156S (1 strain); K163E (1
strain)], site Sb [S190N (1 strain)], that did not appear in pre-
vaccination phase. Among these five variants, one new unique
pH1N1 variant N125D was most frequently observed (9/42,
21.43%). It was first detected on June 6, 2010 and then continued
to circulate afterwards with another 8 strains till the study period
ended in October 2010. During the on-going vaccination
campaign phase (shown as white zone in the middle part of
Figure 3), we observed 2 residue substitutions, H138R and D168G
in site Ca, but these disappeared later on without having been
completely fixed. Another pH1N1 variant G170R, with the only
substitution located at site Ca was present in both pre- and post-
vaccination phases, involving: (1) one strain (isolated on September
8, 2009 in 36
th wk) at the pre-peak period of the epidemic prior to
vaccination and (2) three strains (isolated on June 6, 12 and July 9,
2010) at the post-nation-wide vaccination campaign phase).
Mutations were not evident at the Cb site during the on-going
and post-vaccination phases (Figure 3). Taken together, the
percentages of mutations of Sa sites were significantly higher in
post-nation-wide vaccination phase than pre-nation-wide vaccina-
tion phase (23.40%, 11/47 vs 2.36%, 3/127, p,0.001).
To further understand the effect of the substitutions of amino
acids at the HA1 antigenic sites on the antigenic property of
pH1N1, viruses with different substitutions and isolated in
different time periods of the epidemic were tested for HI with
the six pH1N1 vaccinated human serum samples (ages ranged
from 8–12 years old). The results showed no significant differences
in the HI serotiters among various pH1N1 viruses with different
amino acid substitutions isolated from the early and late periods of
Figure 2. Trends in increasing numbers of amino acids changes of pH1N1-HA in Taiwan, 2009–2010.
doi:10.1371/journal.pone.0031162.g002
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no significant differences between the two strains (A/Taiwan/
NTUD252/2010 and A/Taiwan/NTUT105/2010) with double
mutants (HA: N125D and E374K) and the other two strains (A/
Taiwan/NTU4223/2009 and A/Taiwan/NTU6118/2009) with-
out double mutants and the other substitutions located at Ca site
(K142R, G170R, S203T and D222G) as well, using pH1N1 (A/
California/07/2009 with HA N125N, E374E) vaccinated human
serum. This finding was also confirmed through testing with the
reference pH1N1 virus immunized sheep serum (WHO reagent kit
supported by US-CDC) (Table 2).
Regarding the RBS, only six strains (isolated in Taipei from July
2009 to January 2010) of the 174 sequenced Taiwanese pH1N1
viruses had amino acid residue changes in RBS of pH1N1-HA1
[27,28]. Four strains had substitutions in 220-loop region (residues
218–225), including two strains with D222G substitutions and two
strains with D222E substitutions. The other two strains had
substitutions at 190-helix region (residues 184–191), one with
L191I and the other had S190N substitutions.
Emergence of pH1N1-HA E374K mutants at HA2 of
pH1N1 related to different intervention strategies in
various phases over the epidemic period
Besides the variations of antigenic sites at HA1, we identified
one unique amino acid residue mutation (change from E to K) at
residue 374 which is located at the stalk region of HA2
(Figure 4B,C,D). We then examined the dynamic changes of this
pH1N1-HA E374K (E374K) mutant as it evolved through
different epidemic periods and searched for possible associated
important factors, using both univariate and multivariate analyses.
The E374K mutant was first detected on August 26, 2009 (the 34
th
week of 2009, 3 weeks before the peak of the epidemic) in Taipei
and on October 5, 2009 (the 40
th week - one week before the peak
of the epidemic) in Kaohsiung.
The frequency of the detected E374K mutants was significantly
higher in the post-peak period of the epidemic (§37weeks,
September 13 and later, 2009) than in the pre-peak period (,37
weeks) in both Taipei [63.51% (47/74) vs 9.57% (9/94), p,0.001]
and Kaohsiung [68% (17/25) vs 0% (0/3), p,0.001] (Figure 5).
Taken together, the overall frequency of the identified E374K
mutant was significantly higher in the post-peak period of the
epidemic than those in the pre-peak period [64.65% (64/99) vs
9.28% (9/97), p,0.0001], regardless of geographical variations
(northern vs southern Taiwan) (Figure 5).
Three public health measures, antiviral use, class suspensions
and vaccination, which were implemented sequentially during the
2009 pandemic influenza H1N1, were analyzed in detail to
examine their roles in the viral mutation. In order to understand
the effect of pharmaceutical intervention on the dynamic changes
of E374K, we compared the frequencies of E374K mutants
Figure 3. Dynamic changes of amino acid residues at the antigenic sites of pH1N1-HA in Taiwan, 2009–2010. ,37th Week: Pre-peak
period of the 2009 epidemic; 37th Week: Peak of the 2009 epidemic; .37
th Week: Post-peak period of the epidemic; Green background: Pre-peak
period of the epidemic ; Yellow background: Post-vaccination campaign phase; Strains with red color: pH1N1 strains were isolated from severe cases.
doi:10.1371/journal.pone.0031162.g003
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Oseltamivir (Tamiflu) for treating all ILI patients testing influenza
A antigen-positive on August 1, 2009 (the 30
th week). The positive
rate of pH1N1 still continuously increased and then peaked at
week 37 in northern Taiwan. There was an association between
Tamiflu use and subsequent emergence of E374K [before vs after
initiation use:[0% (0/17) vs 40.78% (73/179), p,0.001]. Howev-
er, using this antiviral drug was not associated with the emergence
of other mutations in the four antigenic sites [before (29.41%, 5/
17) vs after (17.83%, 28/157), p=0.324 (Table 3)].
To further investigate the relationship between temporal
changes in the frequency of E374K mutants and time phases
regarding the other two major public health intervention
strategies, we first analyzed E374K mutants related to the time
phases of class suspension intervention in Taipei City. This was
because the new class suspension policy was implemented when
fall semester started - about two months before the pH1N1
vaccination. The results showed that only three pH1N1 isolates
(4.76%, 3/63) had E374K substitutions detected one week before
the intervention of class suspension (September 1, 2009) (Table 4).
When the fall semester began in early September, E374K mutant
was still present and then sharply increased in the first three
weeks [wks 36–38: 26.32%(5/19), 42.86%(6/14) and 66.67%(2/
3), respectively], despite the nationwide class suspension policy
initiated on September 1, 2009. The frequency of E374K
substitutions increased throughout the epidemic, being much
higher in the pH1N1 strains isolated at the peak of the 2
nd class
suspension wave (weeks 41–45, eg. peak of schoolchildren cases)
than those weeks before class suspension intervention (weeks 34
and before) [100% (6/6) vs 4.76% (3/63), p,0.001] (Table 4).
We then explored E374K mutants before and after implementing
vaccination program by dividing the post-peak epidemic period
into three phases: (1) the peak-epidemic to pre-vaccination [Peak-
Epi-Pre-Vac] phase (week 37–43) was from the peak of the
epidemic (September 13, 2009) to the starting date (November. 1,
2009) of the vaccination program; (2) during implementing
vaccination program [D-Vac] phase (week 44–50) from the
initiation date of pH1N1 vaccination program targeting at health
worker population to one week post nation-wide vaccination
program (November 1-December 19, 2009), and (3) post-national
vaccination [Post-Nat-Vac] phase (.week 50) was one week after
the post-nation-wide vaccination campaign (after December 20,
2009). The frequency of E374K was significantly higher in the
phases of ‘‘during vaccination (D-Vac)’’ (88.2%, 15/17) and
‘‘Post-Nat-Vac’’ (69.1%, 29/42) than in the time interval from
peak-epidemic to pre-vaccination [Peak-Epi-Pre-Vac] phase
(50%, 20/40) (p=0.017) [Table 3,4].
Tempo-spatial analysis of dynamic changes of E374K
mutants
To understand the tempo-spatial spreading of E374K
mutants in different geographical areas, both global spatial
autocorrelation and local cluster correlation analyses of E374K
from week 21 to week 52, 2009 were performed. Using Moran’s
I test to assess global spatial autocorrelation clusters, we found
that pH1N1 cases within weeks 41–52 showed only mild spatial
clustering (Table 5, Figure 6). Furthermore, we performed local
Moran’s I test to check where the spatial clusters were present
during weeks 41–52. The results indicated that seven districts in
Taipei presented significant high-high spatial clusters (Figure
S1).
Besides temporal factors and spatial clusters, univariate analysis
on other factors including gender, age groups and district-specific
population densities did not show any significant differences in the
frequency distribution of E374K mutant stratified by pre-peak and
post-peak periods of the 2009 epidemic (Table 4).
To further identify the role of factors that might simultaneously
affect the dynamic changes of E374K mutants, we used
multivariate logistic regression models considering the variables
of age groups (0–4.9, 5–14.9, 15 and over 15 years old), time
Table 2. Serological comparison in the antibody responses reacted with the pH1N1 isolates with various amino acid substitutions
at different antigenic sites by hemagglutination inhibition (HI) tests.
Virus antigen Amino acid changes HI Serotiters of Anti-pH1N1
Six human serum samples
pH1N1
immune
sheep
serum
2
010
1 020 030 035 053 063
A/California/07/2009 (NYMC X-179A) S203S D222D E374E
N125N K142K G170G
640
4 1280 640 1280 1280 640 2560
A/Taiwan/NTU4223/2009 (7/1/2009) S203T D222G E374E 640 640 320 1280 640 320 2560
A/Taiwan/NTU6118/2009 (9/8/2009) S203T E374E G170R 320 640 320 640 640 320 5120
A/Taiwan/NTU025/2010 (1/6/2010) S203T E374K 640 1280 640 1280 640 640 5120
A/Taiwan/NTUD252/2010 (6/7/2010) S203T E374K G170R N125D 640 640 320 1280 640 320 5120
A/Taiwan/NTUA1281/2010 (6/12/2010) S203T E374K G170R 640 640 320 1280 640 320 2560
A/Taiwan/NTUT105/2010 (8/2/2010) S203T E374K N125D K142R 640 640 320 640 640 320 5120
Pandemic A/H1N1 control antigen
3 5120
1ID numbers of the tested human serum samples.
2ATCC IRR FR188 and.
3ATCC IRR FR-187 in the 2010–2011 WHO Influenza Regent kit for diagnosis of influenza virus from the WHO Collaborating Centers for Surveillance, Epidemiology and
control of Influenza at the U.S. Centers for Disease Control and Prevention.
4HI serotiters: The highest dilution of human serum samples showed complete inhibition of 4 HA units of pH1N1 viruses.
doi:10.1371/journal.pone.0031162.t002
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results indicated that only the time periods and spatial clustering
showed higher odds ratios (OR) [time periods: OR=1.529,
p,0.001, spatial cluster: OR=4.565, p=0.047] after controlling
for the two most important confounders, age and population
density (Table 6).
Global comparison on the temporal distributions of
pH1N1-HA-E374K Mutants in different influenza
transmission zones in 2009
In order to compare the dynamic changes of E374K in Taiwan
with those in other countries, we collected nucleotide sequences of
1462 strains of the 2009 pH1N1 from the NCBI Influenza Virus
Resource and analyzed. The monthly distributions of E374K in
the five WHO influenza transmission zones [29] were shown in
Figure S2. The results indicated that the E374K mutant steadily
increased in Taiwan from August to December, 2009 and became
the major circulated strains close to December in Taiwan [84.62%
(11/13)] and in other Asia countries [50% (7/14)]. Although
E374K mutants were detected earlier in America and Europe
(July, 2009) than in Taiwan (August, 2009), their frequencies were
unstable with fluctuation in the following months without being
fixed early.
Effect of the E374K mutation on the antigenicity and
neutralization activity of HA
To understand the possible effect of an E374K mutation located
at the stalk of HA2 in the cavity where the fusion domain of
mature HA molecules [30,31] might have an impact on the
antigenicity or neutralization activity of pH1N1, we conducted
cross-antibody tests, using the same paired patients’ serum
specimens and virus isolates. Two convalescent serum samples
collected from pH1N1 infected patients, one with wild type viruses
(E374E) and one with the mutant strain (E374K), were employed
for measuring the levels of antibody responses against both strains
simultaneously, using cross HI and MNt tests. By applying
Archetti and Horsfall’s formula [32] for the calculation, the
antigenic difference between the two tested virus strains (when
both viruses and their antisera were compared in cross tests)
represented by the r values for HI and MNt tests, r values of 1.414
and 1, respectively, were generated. An r value of 1 means
‘‘antigenic identity’’. The larger the r value, the less antigenic
relatedness of the two compared virus strains is obtained. In
general, an r value of 4 or greater indicates a significant antigenic
difference between the two tested strains. Table S1 shows that
there was no significant antigenic distance in the antibody levels
measured by HI and MNt tests between the pH1N1 wild-type
(E374E) and E374K mutant strains. We then increased sample
Figure 4. Locations of changed amino acid residues of HA1 and HA2 of pH1N1 virus in Taiwan. A. Globular head of HA1. Site Ca (Red);
Site Cb Orange); Site Sa (Green); Site Sb (Blue). B. Stalk region of HA2. C. Early isolate with E374E residue. D. Late isolate with E374K. All the figures
were generated and rendered with the use of MacPyMOL (http://wwwpymolorg). Numbers of amino acids represents the order of the amino acid
taking out signal peptide (17 amino acids) and then counting the numbers from initial codon.
doi:10.1371/journal.pone.0031162.g004
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31162size to test six pH1N1 strains using six children’s serum samples
with higher serotiters ($1:640) for increasing the sensitivity, the
results still showed there were no significant differences in HI
serological reactions between the wild-type E374E and the E374K
(Table 2). This finding was also confirmed by using the pH1N1-
immunized sheep serum as the reference antibody for HI (Table 2).
Figure 5. Temporal distributions of pH1N1-HA E374K mutants before and after the peak time of epidemics in Taiwan, 2009–2010.
A: Distribution of pH1N1-HA E374 mutants isolated at NTUH (National Taiwan University Hospital). B: Distribution of pH1N1-HA E374 mutants
isolated at YGH.
doi:10.1371/journal.pone.0031162.g005
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31162Investigating the role of pH1N1 virus HA1 variants in
clinical severity
In order to know if the possible association between amino acid
residue substitutions at D222G/E (located at antigenic site Ca) or
temporal increases in frequencies of Q293H in pH1N1 viruses
with clinical severity documented in other countries [15,17,18,33–
35] might also be present in Taiwanese pH1N1 isolates, we
compared the distribution of amino acid substitutions of pH1N1
isolated from patients with mild ILI symptoms (116 cases) versus
those from patients with severe complications (52 cases). To our
surprise, there was no significant difference in the frequency of
pH1N1 with D222G/E or Q293H mutations isolated between ILI
patients with mild and severe complications (Table S2). In
addition, there was no significant association between E374K
mutants or other pH1N1 new variants (N125D, S203T, R205K)
and the severity of clinical outcomes (Table S2). The other
mutations of HA D131E and S186P variants found conferring
viral virulence of A/California/04/2009 pH1N1 adapted in mice
[36], were also not found during our study period.
Analysis of the diversity of amino acid residues of NA in
Taiwanese pH1N1 isolates
Since NA is important for virus release and assisting efficient
replication of influenza virus [8–10], NA nucleotides (1410
nucleotides) from 40 available strains of pH1N1 virus isolated in
Taiwan were collected for analyzing the dynamic changes of
amino acids in the NA. Using the vaccine strain A/California/
7/2009 as a reference, the identities of nucleotides and amino
acids were found to be 99.55% and 99.39% respectively. The
average substitution rates of nucleotides and amino acids were
4.6.610
23 per nucleotide per gene and 6.26.610
23 per amino
acid per protein. The differences in the numbers of amino acid
changes of NA ranged from 2–6. Similar to HA, the tendency of
increasing frequency of more cumulative numbers of amino acid
mutations in NA over different epidemic time periods was also
observed [post-peak period of the epidemic (61.90%, 13/21)
versus pre-peak period of the epidemic (36.84%, 7/19)], though
the pH1N1 with cumulative number of amino acids $3w a sn o t
significantly different between pre- and post–peak epidemic
periods (p=0.205) (Table 1). In addition, all 40 isolates showed
two mutations of V106I and N248D (number from initiation
codon of NA) (Table S3). Besides these two most frequent
residues changes, other sporadic residues substitutions, including
amino acids 4, 10, 11, 16, 19, 34, 66, 82, 84, 119, 166, 188, 189,
242, 309, 329, 365, 381, 382, 394, 416, 426, 435, 448, 452, 453,
462 and 468, also occurred in certain isolates (52.5%, 21/40).
Two mutants are worth mentioning: (1) only one strain (A/
NTU340/2010) had an E119K mutation (2.5%, 1/40) located at
the catalytic site of NA and (2) another strain (A/NTU389/2010)
had N329I mutation (2.5%, 1/40) located at an antigenic site
[37].
Two strains of all the 40 sequenced Taiwanese pH1N1isolates
had co-mutation in the HA and NA regions. One strain, A/
NTU4223/2009 isolated from a mild case on July 15,2009 had co-
substitutions in HA (S203T, D222G) and NA (V106I, V166I,
N248D), and the other strain, A/NTU340/2010 isolated from a
pneumonia case on January 19, 2010 had co-substitutions in HA
(S203T, K163E) and NA (I34T, V106I, E119K, N248D, G382E,
D416N). However, these two co-mutations of HA and NA pH1N1
did not persist in the human population.
Most importantly, none of the 40 analyzed pH1N1 strains had
the H275Y mutation, a site of resistance to oseltamivir.
Analysis of the changes at N-glycosylation sites of HA
and NA
Since the addition of the N-glycosylation site in the globular
head of HA might provide influenza virus with the ability to
evade antibody pressure [38,39], we further analyzed the possible
changes in N-glycosylation sites from Taiwan’s 78 strains of
pH1N1 collected from June 11, 2009 to August 2, 2010 (using A/
California/07/2009 as the reference strain). The results show
that only two strains, A/NTU8112/2009 and A/NTU11/2010
isolated at post-peak epidemic period had lost one N-glycosyla-
tion site of HA at residue 11–13 and 23–25, respectively. All
other 76 strains of pH1N1 strains had the conserved seven N-
glycoslation sites (residues 10, 11, 25, 87, 276, 287 and 481) of
Table 3. Comparison of the percentages of the pH1N1-E374K mutants in HA2 and other variants at the four antigenic sites and
their relationships with different intervention strategies in various epidemic periods, 2009–2010.
Percentages of Mutants
Periods Intervention Strategies HA2 HA1
Number
of isolates E374K
Number
of isolates Ca Cb Sa Sb
Before Aug. 1, 2009 No any intervention 17 0 (0%)
1 17 4* (23.3%)
3 0 (0%) 2* (11.8%)
3 1 (5.9%)
Aug 1–Nov. 18, 2009 Start to pay Tamiflu by
National health Insurance
123 32 (26.0)% 101 9 (9.2)% 2 (2.0%) 1 (1.0%) 1 (1.0%)
Nov.19–Dec 19, 2009 Implement of vaccination
in 6–18 years old
9 7 (77.8%)
2 9 2 (22.2%)
4 0 (0%) 0 (0%)
4 0 (0%)
After Dec 19, 2009 Post nation- wide
vaccination campaign
47 34 (72.3%) 47 4** (8.5%) 0 (0%) 11** (23.4%) 1 (2.1%)
1. The effect of intervention of antiviral agent on the percentages of E374K mutants: Before (0%, 0/17) vs after (40.78%, 73/179), p,0.001 (Fisher’s exact test).
2. The effect of intervention of vaccination on the percentages of E374K mutants: Before (22.86%, 32/140) vs after (72.34%, 41/56), p,0.001 (Fisher’s exact test).
3. The effect of intervention of antiviral agent on the percentages of the pH1N1 variants with substitutions at four antigenic sites (Ca, Cb, Sa, Sb): Before (29.41%, 5/17) vs
after (17.83%, 28/157), p=0.324 (Fisher’s exact test).
4. The effect of intervention of vaccination on the percentages of the pH1N1 variants with substitutions at four antigenic sites (Ca, Cb, Sa, Sb): Before (11.86%, 18/118) vs
after (25%, 15/56), p=0.097 (Fisher’s exact test).
*: Two strains with double mutations in Ca and Sa sites.
**: Three strains with double mutations in Ca and Sa sites.
doi:10.1371/journal.pone.0031162.t003
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146, 235 and 386) of NA were retained in the 40 sequenced
strains.
Summary of pH1N1 Variants in HA and NA
In summary, we identified three fixed mutants at HA and NA of
pH1N1, including (1) the double mutants of NA (V106I and
N248D) that occurred in foreign countries with 0% of wild-type,
(2) S203T mutants also emerged in overseas but with about 5% of
wild-type detected in Taiwan, and (3) E374K started from 0% but
progressively increased and finally replaced most wild-type
pH1N1.
Discussion
Newly emerging influenza pandemics provide the best oppor-
tunity to follow the dynamic changes of viral mutants in the initial
phase as well as after public health measures have been instituted.
We performed such studies in two high-density metropolitan areas
in Taiwan, and made four observations that may enhance our
understanding of influenza epidemiology. First, a significantly
higher cumulative number of amino acid changes in HA and NA
was found in the post-peak period of the epidemic. Second, a
pH1N1 mutant with a unique change E374K in HA2 detected
first at 34
th week in Taipei and 6 weeks later in Kaohsiung,
Table 4. Univariate analysis of the factors associated with the frequency of the pH1N1 HA E374K mutants isolated in Taiwan,
2009–2010.
Factors
Numbers
of isolates E374K
Fisher’s exact
p-values
A. Epidemic periods
1. pre-peak period of the epidemic* (,Wk 37, before September 13, 2009) 97 9 (9.3%)
2. Post-peak period of the epidemic (§Wk 37, September 13, 2009,) 99 64(64.7%) ,0.0001
B. Class suspension in Taipei City
1. Before suspension intervention (,Wk35, before September 1, 2009) 63 3(4.8%)
2. Peak of suspension wave (Weeks 41–45; October 11–November 14,,2009) 6 6(100%) ,0.0001
C. Vaccination program intervention
1. Peak-epidemic to pre-vaccination [Peak-Epi-Pre-Vac](Wk 37–43, September 13–October 31, 2009) 40 20(50%)
2. During vaccination campaign [D-Vac] (Wk 44–50, November 1–December 19, 2009) 17 15(88.2%)
3. Post–national vaccination campaign [Post-Nat- Vac](.Wk 50, After December 20,2009) 42 29(69.%) 0.017
D. Gender Males 118 41(34.8%)
Females 78 32(41%) 0.451
E. Age (Years)
1. Pre-peak period of the epidemic
,12 45 3(6.7%)
12–18 27 4(14.8%)
.18 25 2(8%) 0.552
2. Post-peak period of the epidemic
,12 41 29(70.7%)
12–18 18 12(66.7%)
.18 40 23(57.5%) 0.472
F. Gender and Age
a) Males ,12 52 21(40.4%)
12–18 33 10(30.3%)
.18 33 10(30.3%) 0.534
b) Females ,12 34 11(32.4%)
12–18 12 6(50%)
.18 32 15(46.9%) 0.394
G. Population density
a) Pre-peak period of the epidemic
1) .20000/km
2 42 9.5%(4/42)
2) ,20000/km
2 40 7.5%(3/40) 1
b) Post-peak period of the epidemic
1) .20000/km
2 38 25(69.8%)
2) ,20000/km
2 28 19(67.9%) 1
*: Based on the positive rate detected by RT-PCR or viral culture.
doi:10.1371/journal.pone.0031162.t004
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sion chains and became the major circulating strains in the post-
peak period. Such well-adapted mutants were favored in certain
areas of metropolitan Taipei, where pH1N1 cases had significantly
higher spatial clusters during the peak of the second epidemic
wave (weeks 40–47). Third, tempo-spatial increases in E374K for
six weeks matched well with the second wave of class suspension
(41–45
th weeks). These increasingly dominant mutants persistently
circulated for an additional three weeks before the first day of
vaccination for healthcare workers and continued for two more
weeks before implementing mass-vaccination for schoolchildren.
Fourth, vaccination sharply reduced pH1N1 cases but at 10
months post-vaccination there was still inadequate antibody
pressure to drive antigenic drifts in the circulating new dominant
mutants. These findings imply that continuous selection of
pandemic influenza viruses occurs most frequently at the time
periods and places where numerous transmission events are
happening and stress the importance of prevention measures to
reduce the public health threat.
The higher frequency of cumulative amino acid changes of HA
after the epidemic peak identified in this study can be explained by
several factors. Due to lack of proofreading of viral RNA
polymerase activity, HA has a very high rate of spontaneous
mutation (estimated at 2610
23 base substitutions/position per
virus generation) [40–42]. The quasispecies of pH1N1 virus within
an individual host [43–45] indicate that the intra-host selection of
unique variants in viral populations should occur and subsequently
be transmitted [46]. This natural process leads to selective
advantage variants that continue to circulate in the human
population [42,47–48]. Additionally, the recombination of influ-
enza virus strains within an individual (e.g. intra-host) is also likely
to affect host selection. This might drive the mutated virus variants
with higher replication, better fitness and more efficient transmis-
sibility to have a selection advantage and become the dominant
variant [42].
The phenotypic variations in HA with public health significance
involve five major dimensions: (1) RBS important for viral entry,
Table 5. Global spatial autocorrelation analysis of E374K in
Taipei metropolitan area, 2009.
Epidemic periods
Numbers of
isolates Global Moran’s I p-values
Weeks 21–33 37 Control
Weeks 34–36 48 20.05327 0.451
Weeks 37 14 20.01657 0.836
Weeks 38–40 12 0.00864 0.404
Weeks 41–52 10 0.16498 0.000004
doi:10.1371/journal.pone.0031162.t005
Figure 6. Percentages of pH1N1-HA E374K mutants of 2009 pandemic influenza A (H1N1) in Taipei metropolitan area. (a)–(h):
Different time periods. Green color: virus with E374E; Red color: virus with E374K mutants; The basemap’s color represented the population density.
doi:10.1371/journal.pone.0031162.g006
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virulence and immune escape, (4) clinical severity, and (5)
increasing epidemiological significance. Most pH1N1 viruses with
one or two amino acid residue changes in the antigenic sites of HA
isolated in Taiwan occurred sporadically and were not fixed
during the 2009–2010 epidemic. In the RBS of pH1N1 HA, the
finding of a substitution at the 220-loop region (D222E, D222G),
particularly D222G, reported to be associated with clinical severity
[15,17,18,26,33–35,49], was not supported by our results or other
reports [50–54]. Other RBS mutant such as I216L, which led to
efficient airborne viral transmission in ferrets [55], was also not
found in our study.
Antigenic variation can involve changes in antigenic sites and
glycosylation sites. N125D located at antigenic site Sa of HA,
which was first detected on June 6, 2010 (week 23) (e.g. late
epidemic phase) and circulated through October 2010. All nine
Taiwanese N125D mutants had co-existing E374K mutations,
consistent with the findings from Singapore, Australia and New
Zealand [56]. This N125D antigenic variant, similar to E374K,
appeared after the epidemic peak but with lower frequency,
indicating it had insufficient high immunological pressure to be
fixed. Furthermore, HI serological titers showed no significant
differences between these two strains with double mutants (HA:
N125D and E374K) and the other two strains without double
mutants, using pH1N1 vaccinated human serum and immune
sheep serum. Moreover, the other substitutions located at Ca site
(K142R, G170R, S203T and D222G) also showed no antigenic
changes by HI reaction. These results imply that pH1N1 variants
observed at the beginning of pandemic period had not developed
the capability to escape from immune pressure, regardless of the
cumulative number of amino acid changes identified at the
antigenic sites. In addition, we did not detect any new
glycosylation sites in the HA [57,58]. Taken together, the lower
numbers of cumulative amino acid changes, the less frequent
multiple mutations at four antigenic sites and the lack of additional
glycosylation sites identified in this study support the evidence of
insufficient selection pressure. Immune selection pressure has been
the main driving force for antigenic drift of human seasonal
influenza viruses [59–62]. This was not observed from the
beginning pandemic period in 2009 till ten months after
vaccination.
Our results in Taiwan did not find the three pH1N1 variants,
Q293H, D131E, and S186P, that were associated with clinical
severity. Such an inconsistent finding is likely due to mass
application of antiviral and other public health prevention
measures implemented in Taiwan to reduce viral transmissibility.
This implies that clinically severe cases might have emerged under
special epidemiological settings and searching for these answers
will be helpful for informing future public health prevention
decisions.
After analyzing all pH1N1 variants throughout the epidemic,
this study identified two fixed mutation changes (S203T and
E374K) in HA with epidemiological significance. However, these
two mutations were not significantly co-varied (Fisher’s exact
p=0.08). The overall high percentage (97.13%, 169/174) of
total Taiwanese pH1N1 viruses which had the S203T substitu-
tions is consistent with other reports [54,63–67]. These results
indicate that such substitutions might have occurred before their
introduction to Taiwan. Interestingly, this small change in a side
chain near the monomer-monomer interface appears not to have
had a dramatic effect on the structure of HA [27], nor on HI
titers. In contrast to S203T, the E374K mutation occurred
throughout the epidemic in Taiwan. Application of Tamiflu, that
proved to reduce viral load [68,69], was implemented for all
influenza A antigen-positive ILI patients from Aug 1, 2009 (week
30) and this might have delayed the peak of epidemic before the
vaccination program [70]. When the fall semester began in early
September, the E374K mutant sharply increased in the first
three weeks despite the nationwide class suspension policy
initiated on September 1, 2009. After week 37, pH1N1 variants
strikingly increased the number of amino acid substitutions to
five or more and elevated the percentage of E374K variant
replacing E374E. The class suspension did not stop the
transmission of this E374K mutant, while the percentages of
E374K mutant in the first wave (wks 35–40) and second wave
(wks 41–45) of class suspension in Taipei City were 30.16% (19/
63) and 100% (6/6) respectively. The increased transmission of
pH1N1 might provide more chances to spread E374K mutant in
the human population. The period of high percentage of E374K
mutant matched well with the period before the start of mass
vaccination of pH1N1 in elementary and high schools on
November 16, 2009.
Table 6. Odds ratios for the pH1N1-HA E374K mutants isolated in Taipei City by multivariate logistic regression analysis.
Factors Adjusted Odds Ratios (OR) for Mutant E374K versus Wild type E374E 95% CI of OR p-values
Time
Weeks of the 2009 1.5 1.3, 1.9 ,0.001*
Spatial Cluster
Non-cluster Districts 1
Cluster Districts 4.6 1.0, 20.4 0.047*
Age (Yers)
§15 1
0–4.9 0.1 0.0, 4.0 0.224
5–14.9 1.8 0.6, 5.5 0.338
Population density
Low (,20455/km
2)1
High (.20455/km
2)1 . 4 0.4, 5.5 0.610
Abbreviation : CI, confidence interval; OR: Odds ratio.
*p,0.05.
doi:10.1371/journal.pone.0031162.t006
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increasing dominance of E374K mutants even before vaccination,
supported by spatial epidemiology and multivariate analyses, were
the higher spatial clusters of E374K mutants occurring in the post-
peak of the epidemic period and significantly high spatial
clustering in seven district regions with greater population
densities. Because of the limited number of Taiwanese pH1N1
viruses (n=121) captured in this study, it may be difficult to fully
characterize the impact of the tempo-spatial effects on E374K
mutation. A larger sample size is needed to verify this conclusion.
For the newly emerged pH1N1, most of the persons born after
1957 were susceptible to this virus [71,72]. A lesser level of herd
immunity, that may be insufficient to result in high immune
selection pressure, explains why less substitution of amino acids
and less percentage of E374K mutants were isolated in the early
pre-peak period of the epidemic. In fact, the overall vaccine
coverage rates of pH1N1 in all Taiwan areas and Taipei by
January 29, 2010 were about 24.3%, and 21.8%, respectively [22].
The level of community-based herd immunity plus the extremely
high vaccine coverage (74.7%, 271460/363403, January 29, 2010)
in Taipei’s 7–18 year old school children did reduce the size of the
pH1N1 epidemic and transmission opportunities. Therefore, even
at ten months after the nationwide vaccine campaign, there was
insufficient selection pressure for antigenic drift of pH1N1 in
Taipei. Taken together, all these results strongly support that
E374K widely spread in areas with day-to-day schoolchildren
gatherings even during the period of class suspension and anti-viral
programs. It is very likely that unhygienic behavior, the high-
density public transportation system, crowding, or all of the above
might contribute to the tempo-spatial clustering of E374K
mutants. Thus, the viral population size of the E374K mutant
increased through epidemics, particularly at the pre-vaccination
phase during post-peak periods. Certainly, without anti-viral
agents, class suspension, and vaccination, more virus circulation
and diversities of mutants may have emerged. On the other hand,
the tempo-spatial epidemiological conditions at peaks might
facilitate the selection of more virulent viral variants and thus
confer increasing epidemic severity in later waves with more
fatalities. This happened as documented in past influenza
pandemics [73–75] and other viral pandemics as well [76,77],
once public health interventions had not been timely effective.
These findings indicate that more attention should be paid to non-
pharmaceutical measures [78,79] for future novel influenza viruses
with pandemic potential.
Global comparison of the evolution of the E374K mutations
from June to December of 2009 [19,26,53,63,64] found that lower
numbers of cases with E374K mutation were reported in Canada
(3.4%, 8/235) and Finland (2.38%, 3/126) in the temperate zone
but more cases with this mutation were reported in Taiwan
(37.24%, 73/196) and Singapore [September (14%), October
(28%), November (55%)] in the subtropical and tropical zones
with high population density, respectively [19,53,64]. The roles of
climate, population density, and human-to-human contact behav-
iors in facilitating the fixing of E374K mutants in those particular
regions have not been clarified, indicating that timely international
collaboration is needed among countries in different climate zones
with various epidemiological characteristics once novel influenza
virus emerges in future years.
The virological mechanism that might explain the fitness of
the E374K mutant in the viral population is worth pursuing.
Among several pH1N1 variants, E374K variants were not
evident in the early epidemic period and their fitness would be
random due to the lack of consistent co-substitutions [62,80].
Single residue deletions in the HA fusion peptide can lead to loss
of membrane fusion activity [81], however, the first 24 N-
terminal residues of HA2 were conserved in all the 78 Taiwanese
pH1N1 isolates. No significant differences in cross-MNt and HI
serologic reactions were observed between the wild-type E374E
and the E374K mutant, even using pH1N1-positive human and
sheep serum samples with high titers. More results are needed
with serum samples from patients experienced the 1918
influenza pandemic or with higher B-cell memory responses to
clarify the possible mechanism of immune selection of this
mutant, particularly because the fusion portion of HA2 offers
partial protection for heterologous neutralization [82]. Although
E374K mutants had the similar growth capability in MDCK
cells (Figure S3), other biological characteristics that might be
changed through affecting the stability between oligomers
interaction [19,27,53] or be less recognized or cleared by
immune system facilitating persistent transmission in human
population [83] need further investigation.
In conclusion, this is the first study examining dynamic changes
of pH1N1 viruses through integrating virological surveillance,
tempo-spatial epidemiological characteristics, public health inter-
ventions, clinical severity and serological findings, hopefully
providing fundamental information during the pandemic. This
study had selection bias in the hospitals, patients’ giving specimens,
and fatal cases. A prospective large cohort study that can integrate
with a high quality virological surveillance system through
collecting clinical, epidemiological and intervention attributes,
and meteorological variables plus deep sequencing analysis [84–
86] of virus population random directly from the ILI patients, will
provide the best understanding on the micro- and macro-
mechanisms of viral selection and fitness. Future efforts should
identify the biological significance and explore the mechanisms
involved in the fitness of pH1N1 viruses with amino acid residue
substitutions in RBS sites, antigenic sites and the fusion regions of
HA and their phenotypic characterization with human respiratory
cell lines [87]. Moreover, other segments of the viral genome, such
as NS1 [88] and polymerase genes [89], might impact mutant
fitness, and requires a more detailed investigation. Certainly, real-
time comparative studies on the relationship between intervention
strategies and molecular changes of pandemic influenza virus
through international collaboration will be an important step for
global control of influenza.
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